292 Chapter 12 [35] He, K.; Wang, Y.; Zhong, Y.; Pan, X.; Si, L.; Lu, J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. OncoTargets Ther. 2020, 13, 12601–12613. https://doi.org/10.2147/ott. S279312. [36] Zihui Yong, Z.; Ching, G.T.H.; Ching, M.T.C. Metastatic Profile of Colorectal Cancer: Interplay between Primary Tumor Location and KRAS Status. J. Surg. Res. 2020, 246, 325–334. https:// doi.org/10.1016/j.jss.2018.11.025. [37] Oh, H.H.; Joo, Y.E. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intest. Res. 2020, 18, 168–183. https://doi. org/10.5217/ir.2019.00080. [38] Christensen, T.D.; Palshof, J.A.; Larsen, F.O.; Poulsen, T.S.; Høgdall, E.; Pfeiffer, P.; Jensen, B.V.; Yilmaz, M.K.; Nielsen, D. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. Acta Oncol. 2018, 57, 1057–1062. https://doi.org/10. 1080/0284186x.2018.1433322. [39] Smith, C.G.; Fisher, D.; Claes, B.; Maughan, T.S.; Idziaszczyk, S.; Peuteman, G.; Harris, R.; James, M.D.; Meade, A.; Jasani, B.; et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res. 2013, 19, 4104– 4113. https://doi.org/10.1158/1078-0432.Ccr12-2581. [40] Sepulveda, A.R.; Hamilton, S.R.; Allegra, C.J.; Grody, W.; Cushman-Vokoun, A.M.; Funkhouser, W.K.; Kopetz, S.E.; Lieu, C.; Lindor, N.M.; Minsky, B.D.; et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch. Pathol. Lab. Med. 2017, 141, 625–657. https://doi.org/10.5858/ arpa.2016-0554-CP. [41] Yokota, T.; Ura, T.; Shibata, N.; Takahari, D.; Shitara, K.; Nomura, M.; Kondo, C.; Mizota, A.; Utsunomiya, S.; Muro, K.; et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer 2011, 104, 856–862. https://doi.org/10.1038/ bjc.2011.19. [42] Cheng, H.H.; Lin, J.K.; Chen, W.S.; Jiang, J.K.; Yang, S.H.; Chang, S.C. Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. Int. J. Color. Dis. 2018, 33, 1173–1181. https://doi.org/10.1007/s00384018-3095-6. [43] Sayagués, J.M.; Del Carmen, S.; Del Mar Abad, M.; Corchete, L.A.; Bengoechea, O.; Anduaga, M.F.; Baldeón, M.J.; Cruz, J.J.; Alcazar, J.A.; Angoso, M.; et al. Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. Oncotarget 2018, 9, 24081–24096. https://doi. org/10.18632/oncotarget.25300. [44] Sanz-Pamplona, R.; Lopez-Doriga, A.; Paré-Brunet, L.; Lázaro, K.; Bellido, F.; Alonso, M.H.; Aussó, S.; Guinó, E.; Beltrán, S.; Castro-Giner, F.; et al. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clin. Cancer Res. 2015, 21, 4709–4718. https:// doi.org/10.1158/1078-0432.Ccr-15-0159. [45] Fang, L.; Ford-Roshon, D.; Russo, M.; O’Brien, C.; Xiong, X.; Gurjao, C.; Grandclaudon, M.; Raghavan, S.; Corsello, S.M.; Carr, S.A.; et al. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/ mTOR inhibition. Nat. Commun. 2022, 13, 3181. https://doi.org/10.1038/s41467-022-30794-7. [46] Giannakis, M.; Hodis, E.; Jasmine Mu, X.; Yamauchi, M.; Rosenbluh, J.; Cibulskis, K.; Saksena, G.; Lawrence, M.S.; Qian, Z.R.; Nishihara, R.; et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 2014, 46, 1264–1266. https://doi.org/10.1038/ng.3127. [47] Randon, G.; Fucà, G.; Rossini, D.; Raimondi, A.; Pagani, F.; Perrone, F.; Tamborini, E.; Busico, A.; Peverelli, G.; Morano, F.; et al. Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. Sci. Rep. 2019, 9, 2858. https://doi.org/10.1038/s41598-019-39525-3. [48] Li, X.; Oh, S.; Song, H.; Shin, S.; Zhang, B.; Freeman, W.M.; Janknecht, R. A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer. Oncol. Lett. 2018, 16, 6652–6662. https://doi.org/10.3892/ ol.2018.9487. [49] AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017, 7, 818–831. https://doi.org/10.1158/2159-8290. Cd-17-0151. [50] Poulogiannis, G.; McIntyre, R.E.; Dimitriadi, M.; Apps, J.R.; Wilson, C.H.; Ichimura, K.; Luo, F.; Cantley, L.C.; Wyllie, A.H.; Adams, D.J.; et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc. Natl.
RkJQdWJsaXNoZXIy MTk4NDMw